Bicocca Open Archive

Logo unimib boa
CORTESI, PAOLO ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.818
AS - Asia 12.723
EU - Europa 9.190
SA - Sud America 1.780
AF - Africa 336
OC - Oceania 57
Continente sconosciuto - Info sul continente non disponibili 13
Totale 41.917
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.667
SG - Singapore 4.797
IT - Italia 2.625
CN - Cina 2.385
HK - Hong Kong 1.686
VN - Vietnam 1.674
BR - Brasile 1.329
RU - Federazione Russa 1.303
DE - Germania 1.150
CA - Canada 956
SE - Svezia 709
IE - Irlanda 681
FR - Francia 576
GB - Regno Unito 491
IN - India 427
UA - Ucraina 416
BD - Bangladesh 349
FI - Finlandia 280
ID - Indonesia 225
TR - Turchia 180
NL - Olanda 177
AR - Argentina 171
KR - Corea 156
DK - Danimarca 153
AT - Austria 146
IQ - Iraq 128
MX - Messico 121
ZA - Sudafrica 105
ES - Italia 100
PK - Pakistan 95
PH - Filippine 77
JP - Giappone 76
SA - Arabia Saudita 72
CH - Svizzera 68
PL - Polonia 68
EC - Ecuador 66
BE - Belgio 51
VE - Venezuela 51
IR - Iran 50
CO - Colombia 48
UZ - Uzbekistan 48
AU - Australia 47
CL - Cile 44
MA - Marocco 40
AE - Emirati Arabi Uniti 33
EG - Egitto 32
KE - Kenya 32
TH - Thailandia 32
MY - Malesia 30
ET - Etiopia 28
TN - Tunisia 25
CZ - Repubblica Ceca 24
JO - Giordania 24
NP - Nepal 23
PT - Portogallo 23
PY - Paraguay 22
RO - Romania 22
TW - Taiwan 21
PE - Perù 20
DZ - Algeria 19
JM - Giamaica 18
BG - Bulgaria 17
AL - Albania 16
BO - Bolivia 15
IL - Israele 15
LT - Lituania 15
KG - Kirghizistan 13
OM - Oman 13
DO - Repubblica Dominicana 12
LB - Libano 12
AZ - Azerbaigian 11
EU - Europa 11
GR - Grecia 11
NO - Norvegia 11
CR - Costa Rica 10
LK - Sri Lanka 10
UY - Uruguay 10
NG - Nigeria 9
KZ - Kazakistan 8
MD - Moldavia 8
RS - Serbia 8
BH - Bahrain 7
BY - Bielorussia 7
GT - Guatemala 7
MN - Mongolia 7
NI - Nicaragua 7
NZ - Nuova Zelanda 7
SI - Slovenia 7
HU - Ungheria 6
KW - Kuwait 6
PS - Palestinian Territory 6
SN - Senegal 6
GA - Gabon 5
HR - Croazia 5
GE - Georgia 4
GH - Ghana 4
HN - Honduras 4
LU - Lussemburgo 4
QA - Qatar 4
SK - Slovacchia (Repubblica Slovacca) 4
Totale 41.834
Salva come PNG Salva come JPEG
Città #
Singapore 2.356
Ann Arbor 1.847
Hong Kong 1.658
Ashburn 1.533
San Jose 1.347
Fairfield 858
Woodbridge 833
Chandler 728
Toronto 714
Houston 703
Frankfurt am Main 658
Dublin 654
Milan 635
Wilmington 566
New York 513
Ho Chi Minh City 506
Santa Clara 439
Hanoi 417
Seattle 390
Jacksonville 388
Dearborn 345
Beijing 328
Los Angeles 327
Dallas 311
The Dalles 297
Chicago 293
Cambridge 280
Princeton 278
Council Bluffs 263
Hefei 251
Lauterbourg 171
Jakarta 159
Boardman 151
Helsinki 148
Nanjing 146
Seoul 132
São Paulo 132
Buffalo 129
Altamura 128
Lawrence 124
Rome 123
Moscow 110
Vienna 107
Shanghai 102
Orem 100
Munich 91
London 79
Guangzhou 78
Da Nang 65
San Diego 64
Tokyo 61
Haiphong 60
Lachine 60
Nuremberg 59
Rio de Janeiro 53
Andover 51
Baghdad 50
Chennai 50
Hangzhou 48
Nanchang 48
Johannesburg 47
Warsaw 47
Denver 46
Lappeenranta 45
Shenyang 45
Montreal 44
Columbus 43
Dong Ket 43
Tianjin 43
Zurich 43
Phoenix 42
Washington 41
Paris 38
Tashkent 38
Boston 37
Amsterdam 36
Brooklyn 36
Mexico City 36
Ottawa 36
Bologna 35
Mumbai 35
Poplar 35
Brussels 34
Fremont 34
Jinan 34
Changsha 33
San Francisco 33
Atlanta 32
Can Tho 31
Dhaka 31
Istanbul 31
Brasília 30
Zhengzhou 30
Jiaxing 29
Naples 29
Verona 29
Biên Hòa 28
Hebei 28
Lahore 28
New Delhi 28
Totale 25.038
Salva come PNG Salva come JPEG
Nome #
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 590
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 564
Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women 475
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 452
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 445
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review 436
Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023 434
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors 415
State of health and inequalities among Italian regions from 2000 to 2021: a systematic analysis based on the Global Burden of Disease Study 2021 401
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 392
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 387
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017 378
Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis 370
Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 364
Use of health care administrative databases to estimate the burden of breast cancer. 360
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 359
Use of health care administrative databases to estimate the burden of multiple sclerosis: a population-based study 353
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 346
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 337
Liver Transplantation in Alcohol-Associated Hepatitis. Benefits and Limitations of Psychosocial Selection and Support in Alcohol Relapse. The Experience of a Tertiary Center in Italy 325
Health related quality of life in chronic liver diseases 325
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 324
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 323
Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017 322
Costs and effectiveness of influenza vaccination: A systematic review 318
Trattamento con Sofosbuvir e Ribavirina nei pazienti hcv-positivi listati per il trapianto di fegato: un analisi di costo-efficacia 317
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 317
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 313
The socioeconomic burden of patients affected by hemophilia with inhibitors 312
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 304
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 300
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 300
The impact of liver disease on the health-related quality of life 294
Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 290
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 288
Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis 288
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 286
P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 286
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 285
Characteristics of patients with Chronic Hepatitis C who have failed past treatment or who have never been treated: How much room left for Interferon? 282
Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting 280
Time-Trends in Air Pollution Impact on Health in Italy, 1990–2019: An Analysis From the Global Burden of Disease Study 2019 278
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 278
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 276
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities 275
Sustainability of the Italian National Health Service 274
Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 272
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 271
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 271
Azithromycin use and outcomes in patients with COVID-19: an observational real-world study 269
Health Related Quality of Life in the Major Liver Conditions 267
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors 266
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 264
Models of The Impact of Major Liver Diseases on Eq-5d Visual Analogue Scale and Utility-Index: Convergences and Divergences 263
Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: A systematic analysis for the Global Burden of Disease Study 2017 262
Difference in health related quality of life of chronic liver diseases and general population 261
Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 260
Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study) 257
Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options 256
Sofosbuvir-based all-oral treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis 254
Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions 254
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 253
PGI31 Health Care Indicators to Measure Quality of Care in Patients with Liver Diseases 251
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? 247
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study 247
Health related quality of life norm data of the general population in Italy: Results using the EQ-5D-3L and EQ-5D-5L instruments 246
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 246
Treatment patterns in essential tremor: Real-world evidence from a United Kingdom and France primary care database 246
Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era 243
COVID-19 outbreak impact on anticoagulants utilization: an interrupted time-series analysis using healthcare administrative databases 242
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017 240
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 240
2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation 238
The Burden of Severe Hypoglicaemias and Diabetes Ketoacidosis: A Population-Based Study 237
Should Sofosbuvir-Based All-Oral Treatment Be Considered In Elderly Chronic Hepatitis C Patients? 237
Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products 236
Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 235
Economic Burden of Urticaria Requiring Hospitalization: Analysis from an Administrative Database 235
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 235
Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view 235
Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database 234
Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 234
Il burden delle polmoniti: analisi dai database amministrativi (DENALI) della regione Lombardia. 232
PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases 232
Preferenze della popolazione italiana per gli stati di salute dell'EQ-5D 229
Economic Burden Of Stroke: Analysis From An Administrative Database 228
Incidence of inhibitors to recombinant factor VIII products – A meta-analysis of 1,852 previously untreated patients 227
The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation 226
Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis 225
Utilization of disease modifying agents in multiple sclerosis: from an Italian administrative database. 223
Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study 223
Management of chronic hepatitis C (Chc) genotype 1 treatment-naïve patients in an era of rising opportunities and costs: A cost-effectiveness analysis 221
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 221
Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases 220
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting 220
Italian population-based values of EQ-5D health states 218
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy 218
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review 214
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 214
Cardiovascular diseases burden in Italy, 1990–2017: the Global Burden of Disease Study 214
Totale 28.927
Salva come PNG Salva come JPEG
Categoria #
all - tutte 138.208
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 138.208
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021268 0 0 0 0 0 0 0 0 0 0 0 268
2021/20221.868 137 182 253 178 130 146 64 121 109 129 106 313
2022/20233.149 327 896 275 271 212 452 57 195 222 49 100 93
2023/20242.714 98 119 93 149 295 645 397 119 233 114 146 306
2024/20257.707 352 716 355 366 610 469 444 293 795 929 1.013 1.365
2025/202618.240 2.107 1.037 1.194 1.799 2.071 1.059 2.630 798 1.441 1.926 1.554 624
Totale 43.198